Events

2025 EU MITRE ATT&CK® Community Workshop
MAY
Thu
15
09:30 - 17:00

Starts in 3 days from now

Location

Hybrid - Brussels and online

Programmes
Security Cybersecurity Defence EDF

Hosted by Eurocontrol and supported by the MITRE Center for Threat-Informed Defense and the Centre for Cybersecurity Belgium (CCB), this full-day hybrid event is built by practitioners, for practitioners. Topics covered include detection engineering, red teaming, or national cyber defense.

The agenda features expert talks on:

  • Applying ATT&CK for resilience and critical infrastructure
  • AI-driven red teaming and detection
  • Cyber insurance and risk-based threat modeling
  • Insights directly from MITRE, CIS, CERT-UA, EC, and more

More information and the possibility to register can be found on the event website.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.